Narcolepsy: Epidemiology Forecast to 2027
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Narcolepsy is a chronic disorder that is mainly characterized by excessive daytime sleepiness and, in the majority of individuals, cataplexy—a sudden loss of muscle tone during wakefulness that is evoked by strong, usually positive, emotions. The onset of narcolepsy is during adolescence or early adulthood. While the exact cause of narcolepsy is unknown, the majority of cases have low levels of hypocretin, an important neurochemical that helps regulate wakefulness and rapid eye movement (REM) sleep.
GlobalData’s epidemiological forecast is supported by country-specific data, which provide detailed insights into the epidemiology of the disease in each market. GlobalData epidemiologists used nationally representative, country-specific studies published in peer-reviewed journals of national healthcare databases and registries to forecast the total and diagnosed prevalent cases of narcolepsy in the 7MM. In addition, GlobalData epidemiologists used sources that provided uniform diagnostic criteria as defined by the International Classification of Sleep Disorders (ICSD-3).
In the 7MM for 2017, the US accounted for 40.75% of the total prevalent cases of narcolepsy, 5EU combined made up 44.33% of the total prevalent cases of narcolepsy, and Japan accounted for 14.91% of the total prevalent cases of narcolepsy. In 2017, the 7MM had 378,279 total prevalent cases of narcolepsy. This is expected to increase to 393,534 cases by 2027, at an annual growth rate (AGR) of 0.40%. With the advent of objective testing, there could be an increase in the timely diagnosis, diagnosis rate, and treatment of patients with narcolepsy.
Scope
The Narcolepsy Epidemiology Forecast Report and Epidemiology Forecast Model provide an overview of the risk factors and global trends of narcolepsy in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
This report also includes 10-year epidemiology forecast of the total prevalent cases (both diagnosed and undiagnosed) and diagnosed prevalent cases of narcolepsy in these markets from 2017–2027. Both types of prevalent cases are further segmented by sex and age (15–39 years, 40–59 years, 60–79 years, and 80 years and older) and by type (NT1 and NT2).
The narcolepsy epidemiology forecast report and model were written and developed by Masters- and PhD-level epidemiologists.
The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 7MM.
The Epidemiology Forecast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Reasons to Buy
The Narcolepsy Epidemiology Forecast series will allow you to:
Develop business strategies by understanding the trends shaping and driving the global narcolepsy market.
Quantify patient populations in the global narcolepsy market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for narcolepsy therapeutics in each of the markets covered.
Understand magnitude of narcolepsy population by type 1 and type 2 forms.
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.